CompletedEarly Phase 1NCT00795457
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ian F. Pollack, M.D.
- Principal Investigator
- Frank Lieberman, MDUniversity of Pittsburgh Medical Center
- Intervention
- GAA/TT-peptide vaccine and poly-ICLC(biological)
- Enrollment
- 13 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2015
Study locations (2)
- Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Collaborators
Oncovir, Inc. · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00795457 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE4NCT03975829Pediatric Long-Term Follow-up and Rollover StudyNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT03739372Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade GliomaUniversity of California, San Francisco